EGFR-IN-165 

EGFR-IN-165 is a potent EGFR inhibitor. EGFR-IN-165 demonstrates superior potency with IC₅₀s of 17.18 and 64.74 nM against EGFR^L858R/T790M and EGFR^WT; 2.17 and 6.2 μM against NCI-H1975 cells and A431 cells. EGFR-IN-165 significantly inhibits the migration and induces G1 phase cell cycle arrest and cell apoptosis. EGFR-IN-165 can be used for the study of cancers such as non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinoma^[1].

EGFR-IN-165 (Compound 4b) (0-5 μM, 48 h) effectively inhibits EGFR phosphorylation in a concentration-dependent manner in A431 cells and NCI-H1975 cells^[1].
EGFR-IN-165 (1.25-10 μM, 24 h) effectively inhibits the migration of A431 cells at a concentration of 10 μM^[1].
EGFR-IN-165 (2.5-20 μM, 48 h) reaches 12.91% apoptosis rate in NCI-H1975 cells at a concentration of 20 μM^[1].
EGFR-IN-165 (2.5-20 μM, 24-48 h) induces cell cycle arrest in the G1 phase of NCI-H1975 cells^[1].
EGFR-IN-165 has superior stability with a half-life of 38.5 h in human plasma and a low clearance rate in liver microsomes with an intrinsic clearance rate of 24.3 mL/min/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

483.48

C₂₆H₂₁N₅O₅

COC1=C(C=C2C(N=CN=C2NC3=CC=C(C(C)=C3)C(OC4=NN=C(O4)C5=CC=CC=C5)=O)=C1)OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tang Z, et al. Design, synthesis, and evaluation of 1,3,4-oxadiazole-based EGFR inhibitors. Bioorg Med Chem Lett. 2025 Nov 1;127:130315.  [Content Brief]